Skip to main content
. 2023 Oct 20;10(11):ofad516. doi: 10.1093/ofid/ofad516

Figure 2.

Figure 2.

EBV-miR-BART17-3p directly targeted DDX3X. A, Matching results between the DDX3X 3′-UTR region and the EBV-miR-BART17-3p sequence, including the wild type and mutant type of the matching sequence. B, Negative control (DDX3X-NCs), wild type (DDX3X-WT), or mutated (DDX3X-MUT) plasmids were cotransfected with EBV-miR-BART17-3p mimics or miR-NCs into HEK293T cells. The luciferase activities were measured for 24 hours. Statistical analysis was performed with analysis of variance. NS, not significant (P > .05). **P < .01. C, The relative expression levels of EBV-miR-BART17-3p were measured in B-cell lines (NCI-BL2009 and Raji) and NK-cell lines (KAI3, SNK-6, IMC-1, NKYS, YT, and NK92). D, The protein expression level of DDX3X was detected in B-cell lines (NCI-BL2009 and Raji) and NK-cell lines (KAI3, SNK-6, IMC-1, NKYS, YT, and NK92). E, Comparison of DDX3X expression levels among NK-cell lines (NKYS, IMC-1, KAI3) transfected with EBV-miR-BART17-3p negative controls, inhibitors, or mimics. Data are presented as mean ± SD. EBV, Epstein-Barr virus; MUT, mutated; NC, negative control; NK, natural killer; WT, wild type.